A New Lens on Tumor Immunology

At NetwoRx Bio, we decode and map the complex communication between immune, tumor, and stroma cells within the tumor microenvironment.

Using proprietary computational tools, we generate the ‘NetwoRx Map Score’ – a patient-specific metric that identifies the most relevant molecular interactions.

This score is designed to predict response to immunotherapeutic drugs (ICI), monoclonal antibodies and small molecule immune modulators – unlocking the next generation of immunotherapy.

Our Value Proposition

01
Optimal Clinical Trial Design

Matching single drugs or combinations of immunotherapeutic drugs to specific cancer indications and patients

02
Precision Medicine

Personalizing treatment strategies for an individual patient

shap

The Need

Limited understanding of tumor-stroma-immune interactions
within the tumor microenvironment leads to:

20% - 30%
20% - 30% Patient Response Rates

  • treatment
    $100,000+ per single treatment
  • networx
    Non-responders face delayed alternative treatments and frequently suffer immune adverse effects
  • networx
    The strongest predictive biomarker has only about 60% accuracy

>90% Failure Rate
in Solid Cancer Clinical Trials

  • treatment
    Thousands of running trials annually cost billions, yet only ~1/30 reaches clinical approval clinical approval
  • networx
    Out of 300 potential targets, most drug candidates remain untested across the majority of cancers

We Uniquely Explore
the Immuno-Tumor Interactions

01

We integrate unique data of over 30 immune subsets, stroma, and tumor cells – an exceptionally reproducible data, including cell frequencies and deep transcriptomes of all physically sorted immune, tumor and stroma cells

02

We employ unique computational tools to map and score communication networks formed between these cells

03

We generate “NetwoRx Map Score’ per each molecular interaction (e.g. the PD1-PDL1) per each patient which provides unprecedented depth into understanding the immune communication within tumors

04

Initial data show a strong correlation between the ‘NetwoRx Map Score’ and ICI drug effectiveness, suggesting it can predict responses to specific drugs and combinations — both for individual patients and cancer types

shap

Initial clinical data suggest that NetwoRx Bio Map Scores can predict individual patients' clinical benefit from IO or biological therapy in a cancer agnostic manner

Our Work in Progress

We already have highly detailed and comprehensive data for Renal and Bladder cancers, and we are in process of establishing the same for Liver, Lung, Colon, Brain, and Gastric cancers

Join us to increase the probability of your clinical
trial success

Developing
a drug?

We offer to use our system to help identifying effective drug combinations aiming to enhance patient outcomes

Looking for an additional
cancer indication?

We offer to predict patients’ response rates, ahead of a clinical trial, to expand your drug’s potential

Leading Team

Ori Choshen
CEO, Co-founder, Board member

CEO of VLX Ventures, founded 10+ biotech and computational biology startups.

DR. Ilan Volovitz, PH.D.
Co-founder, Chief Scientific Officer

Head of the Cancer Immunotherapy lab The Neurosurgery dep.
Tel-Aviv Sourasky MC

DR. Ravit Geva, M.D.
Co-founder, Chief Medical Officer

Head of the oncology clinical research unit, Deputy director – Oncology division
Tel-Aviv Sourasky MC


DR. Efrat Elis, PH.D.
Head of Computation

Kelly Lipczyc
Head of Lab

Board Members

Ori Choshen
CEO, Co-founder, Board member

DR. Anat Cohen-Dayag, PH.D.
Compugen President & CEO
(NASDQ: CGEN)

Shap
Shap